Journal: The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry
Article Title: Cognition and Dopamine D 2 Receptor Availability in the Striatum in Older Patients with Schizophrenia.
PMID/MRN: 27745822
Publication Date: 2016-Aug-02
Abstract:
To assess the impact of reducing the dose of antipsychotics on cognition and dopaminergic D 2 receptor availability in the whole striatum, and identify their relationship in patients with schizophrenia aged 50 years or older.
Open-label prospective PET [ 11 C]-raclopride study.
A tertiary care center outpatient setting.
Thirty-seven clinically stable participants with schizophrenia or schizoaffective disorder, aged 50 years or greater, and having been treated with olanzapine or risperidone monotherapy at the same dose for at least 6 months.
Gradual reduction in their olanzapine or risperidone daily dose of up to 40%.
Clinical and cognitive assessments, and [ 11 C]-raclopride PET to determine D 2 receptor availability at baseline and after the dose reduction. Main outcome measures were overall cognition and D 2 receptor availability in whole striatum.
Reducing the antipsychotic dose resulted in an increase in D 2 receptor availability in the whole striatum and an association between D 2 receptor availability and overall cognition despite lack of change in the latter. There was also an association between change in D 2 receptor availability and change in overall cognition.
Our findings suggest that optimizing D 2 receptor availability by reducing antipsychotic dose allows this system to contribute more significantly to cognitive function in patients with schizophrenia. This uncovered association could be harnessed by cognitive-enhancing interventions.
Copyright © 2016 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights reserved.